Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced that it will release its full year 2022 results and a corporate update on March 23, 2023. The release will be followed by a conference call at 8:30 a.m. EDT / 13:30 CET for shareholders and stakeholders.

The call will be accessible via phone and webcast, with a replay available for 30 days following the event. Affimed specializes in immuno-oncology, focusing on harnessing the innate immune system to combat cancer through its proprietary ROCK® platform, which facilitates the development of innovative therapies targeting various tumors.

HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.

The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://register.vevent.com/register/BIbfecf0c35a2946dc88d3ae439cb5d3e2, and you will be provided with dial-in details and a pin number.

Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will be accessible at the same link for 30 days following the call.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK^® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK^® platform predictably generates customized innate cell engager (ICE^®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE^®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

What are the details of Affimed's conference call on March 23, 2023?

Affimed's conference call will take place at 8:30 a.m. EDT / 13:30 CET on March 23, 2023, following the release of its full year 2022 results. It will be available via phone and webcast.

How can I access the webcast for Affimed's results?

The live audio webcast can be accessed in the 'Webcasts' section of Affimed's 'Investors' page on their website.

What does Affimed specialize in?

Affimed is a clinical-stage immuno-oncology company focused on using the innate immune system to fight cancer, utilizing its ROCK® platform for innovative therapy development.